HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism.

Abstract
CPI-613 is a novel anti-tumor compound with a mechanism-of-action which appears distinct from the current classes of anti-cancer agents used in the clinic. CPI-613 demonstrates both in vitro and in vivo anti-tumor activity. In vitro metabolic studies using liver S9 were performed which demonstrated that CPI-613 undergoes both phase 1 (oxidation) and phase 2 (glucuronidation) transformations. Its metabolic half-life varied between species and ranged from 8 minutes (Hanford minipig) to 47 minutes (CD-1 mouse). We performed metabolite mass assessments using selected in vitro incubation samples and demonstrated that +16 amu oxidation with and without +176 amu glucuronidation products were generated by human and animal liver S9. LC/MS/MS fragmentation patterns showed that an uncommon sulfoxide metabolite was formed and the O-glucuronidation occurred at the terminal carboxyl moiety. We observed that the +192 amu sulfoxide/glucuronide was generated only in human liver S9 and not by any of the other species tested. Synthetic metabolites were prepared and compared with the enzymatically-generated metabolites. Both the chromatographic retention times and the LC/MS/MS fragmentation patterns were similar, demonstrating that the synthetic metabolites were virtually identical to the S9-generated products. CYP450 reaction phenotyping and inhibition data both suggested that multiple CYP isozymes (2C8 and 3A4, along with minor contributions by 2C9 and 2C19) were involved in CPI-613 metabolism and sulfoxide formation. Plasma samples from human subjects dosed with CPI-613 also contained the sulfoxide ± glucuronide metabolites. These results show that the in vitro- and in vivo-generated phase 1 and phase 2 metabolites were in good agreement.
AuthorsKing C Lee, Robert Shorr, Robert Rodriguez, Claudia Maturo, Lakmal W Boteju, Adrian Sheldon
JournalDrug metabolism letters (Drug Metab Lett) Vol. 5 Issue 3 Pg. 163-82 (Aug 2011) ISSN: 1874-0758 [Electronic] United Arab Emirates
PMID21722089 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Caprylates
  • Glucuronides
  • Sulfides
  • Sulfoxides
  • devimistat
Topics
  • Animals
  • Antineoplastic Agents (metabolism, pharmacology)
  • Caprylates (metabolism, pharmacology)
  • Cell Line, Tumor
  • Chromatography, Liquid
  • Glucuronides (metabolism)
  • Half-Life
  • Humans
  • Liver (metabolism)
  • Mice
  • Microsomes, Liver (metabolism)
  • Neoplasms (drug therapy, pathology)
  • Oxidation-Reduction
  • Rats
  • Rats, Sprague-Dawley
  • Species Specificity
  • Sulfides (metabolism, pharmacology)
  • Sulfoxides (metabolism)
  • Swine
  • Swine, Miniature
  • Tandem Mass Spectrometry

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: